|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.29/-1.19
|
企业价值
250.27M
|
资产负债 |
每股账面净值
4.77
|
现金流量 |
现金流量率
--
|
损益表 |
收益
2.81M
|
每股收益
0.05
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/11 16:39 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. |